comscoreTop Metastatic Breast Cancer Research at ASCO 2019

Top Metastatic Breast Cancer Research at ASCO 2019

Dr. Maura Dickler offers an overview of some of the most interesting research on metastatic breast cancer presented at the 2019 ASCO Annual Meeting.
Jun 14, 2019
00:00
Download
00:00

Dr. Maura Dickler offers insights on some of the most interesting research on metastatic breast cancer presented at the 2019 American Society of Clinical Oncology Annual Meeting.

Listen to the podcast to hear Dr. Dickler explain:

  • results from the IMpassion 130 trial looking at Tecentriq (chemical name: atezolizumab) and Abraxane (chemical name: albumin-bound or nab-paclitaxel) to treat metastatic triple-negative breast cancer

  • results from the Young-PEARL trial studying Ibrance (chemical name: palbociclib) and Aromasin (chemical name: exemestane) along with ovarian suppression to treat premenopausal women diagnosed with hormone-receptor-positive metastatic breast cancer

  • overall survival results from the MONALEESA-7 trial, which examined using Kisqali (chemical name: ribociclib) and hormonal therapy to treat premenopausal women diagnosed with hormone-receptor-positive, HER2-negative advanced-stage breast cancer

About the guest
 
Maura Dickler headshot
Maura Dickler, MD

Dr. Maura Dickler is the vice president of oncology late phase development for Eli Lilly and Company.

— Last updated on May 5, 2022, 6:35 PM

 
Lilly Oncology

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate